Acebutolol Pregnancy and Breastfeeding Warnings
Acebutolol is also known as: Sectral
Acebutolol Pregnancy Warnings
Acebutolol has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. Some studies in human pregnancy have shown decreased fetal heart rate, blood pressure, and birth weight relative to controls and patients given other antihypertensive agents. Acebutolol should only be given during pregnancy when need has been clearly established.
Acebutolol has been used safely for the treatment of maternal hypertension during pregnancy. Experience with acebutolol, especially during the first trimester, is limited. Although acebutolol crosses the human placenta, no reports of congenital malformations associated with acebutolol are reported. A controlled study comparing acebutolol to methyldopa in 20 pregnant women revealed no significant hemodynamic effect on the newborns and no differences between the drugs for pregnancy duration, birth weight, Apgar scores, or placental weight. Some studies, however, have shown that transient hypoglycemia and bradycardia are more likely in neonates whose mothers were taking acebutolol relative to mothers who were taking methyldopa. It is recommended that neonates whose mothers were taking acebutolol be monitored for signs of beta-blockade (bradycardia, hypotension, hypoglycemia) for at least 48 hours postpartum.
Acebutolol Breastfeeding Warnings
At least one nursing infant whose mother was taking acebutolol developed hypotension, bradycardia, and transient tachypnea after breast-feeding. Since acebutolol concentrates in human milk, it is recommended that nursing infants be monitored for signs and symptoms of beta-blockade during breast-feeding.
Acebutolol and its metabolite diacetolol are secreted into human milk with milk plasma ratios of 7:1 and 12:2 respectively. Side effects, such as hypotension, bradycardia, and other signs of beta-blockade have been reported in nursing infants. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.